Galanin in Alzheimer disease.
Galanin (GAL) and GAL receptors (GALR) are overexpressed in limbic brain regions associated with cognition in Alzheimer disease (AD). The functional consequences of this overexpression are unclear. Because GAL inhibits cholinergic transmission and restricts long-term potentiation in the hippocampus, GAL overexpression may exacerbate clinical features of AD. In contrast, GAL expression increases in response to neuronal injury, and galaninergic hyperinnervation prevents the decreased production of protein phosphatase 1 subtype mRNAs in cholinergic basal forebrain neurons in AD. Thus, GAL may also be neuroprotective for AD. Further elucidation of GAL activity in selectively vulnerable brain regions will help gauge the therapeutic potential of GALR ligands for the treatment of AD.
Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, 2242 West Harrison Street, Chicago, IL 60612, USA. emufson@rush.edu
Scott E
SE
Counts
Sylvia E
SE
Perez
Stephen D
SD
Ginsberg
Sonsoles
S
De Lacalle
Elliott J
EJ
Mufson
D000544:Alzheimer Disease / Q000235:genetics* / Q000378:metabolism* / Q000628:therapy; D000818:Animals; D001921:Brain / Q000378:metabolism* / Q000473:pathology; D019004:Galanin / Q000502:physiology*; D006801:Humans; D051379:Mice; D008954:Models, Biological; D016548:Prosencephalon / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism
D012333:RNA, Messenger; D019004:Galanin